{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "BLCO",
  "name": "Bausch + Lomb Corporation",
  "url": "https://frontierpicks.com/dossiers/BLCO/",
  "json_url": "https://frontierpicks.com/dossiers/BLCO.json",
  "status": "WATCHLIST",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Bausch + Lomb's shares are more likely to lag the S&P 500 over three months: a 24.1% rise to $21.09 on 13 November 2026 already reflects the third 2026 guidance raise, and an interim CEO and a parent-controlled separation leave the upside on an undated event; the fourth-quarter report, due early in 2027, is the next scheduled test.",
  "invalidation_trigger": "A daily close above $23.00, above RBC Capital's $23 target of 2026-10-29 (the highest of the post-results targets cited here), which would show the shares leading; or a signed agreement by Bausch Health to sell Bausch + Lomb outright.",
  "catalyst_date": "2027-02-25",
  "catalyst_estimated": true,
  "portfolio": null,
  "pick": null,
  "themes": [
    "medtech-diagnostics",
    "m-and-a-special-situations"
  ],
  "tags": [],
  "sources": [],
  "caveats": [
    {
      "claim": "Bausch + Lomb is controlled by Bausch Health, which holds about 87% of its shares and decides whether and how to sell or distribute the stake.",
      "source": "Bausch Health Form 10-Q for the quarter ended 2026-09-30",
      "as_of": "2026-09-30"
    },
    {
      "claim": "The interim CEO, Thomas Appio, also serves as chief executive of the controlling shareholder, Bausch Health.",
      "source": "Bausch + Lomb Form 8-K filed 2026-10-13",
      "as_of": "2026-10-13"
    }
  ],
  "source_links": [
    {
      "title": "Bausch & Lomb Corp - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001860742/000186074226000108/ex991q3-2026.htm",
      "date": "2026-10-28"
    },
    {
      "title": "Bausch Health Companies Inc. - Form 10-Q - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0000885590/000088559026000123/bhc-20260930.htm",
      "date": null
    },
    {
      "title": "Bausch + Lomb names Appio interim CEO as Saunders hits the exit again",
      "url": "https://www.fiercepharma.com/pharma/bausch-lomb-names-appio-interim-ceo-saunders-hits-exit-again",
      "date": null
    },
    {
      "title": "Bausch Health (BHC) Q3 2026 Earnings Call Transcript",
      "url": "https://www.fool.com/earnings/call-transcripts/2026/10/29/bausch-health-bhc-q3-2026-earnings-call-transcript/",
      "date": "2026-10-29"
    },
    {
      "title": "Bausch + Lomb Posts Strong Third Quarter Results, Raises Full-Year Guidance",
      "url": "https://www.visionmonday.com/business/international-news/article/bausch-lomb-posts-strong-third-quarter-results-raises-fullyear-guidance-1/",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter revenue was $1,375 million, up 7% as reported and 8% in constant currency. Vision Care was $774 million, Surgical $234 million and Pharmaceuticals $367 million.",
      "source": "Bausch + Lomb third-quarter 2026 results release (Form 8-K, exhibit 99.1)",
      "as_of": "2026-10-28"
    },
    {
      "claim": "Adjusted EBITDA excluding acquired research was $325 million, against $243 million a year earlier. Net income attributable to the company was $32 million, against a $28 million loss.",
      "source": "Bausch + Lomb third-quarter 2026 results release (Form 8-K, exhibit 99.1)",
      "as_of": "2026-10-28"
    },
    {
      "claim": "The 2026 outlook was raised to revenue of $5,450–5,550 million and adjusted EBITDA of $1,090–1,140 million, from $5,440–5,540 million and $1,025–1,075 million.",
      "source": "Bausch + Lomb third-quarter 2026 results release (Form 8-K, exhibit 99.1)",
      "as_of": "2026-10-28"
    },
    {
      "claim": "CEO Brent Saunders stepped down. Chairman Thomas Appio was named interim CEO and remains CEO of Bausch Health.",
      "source": "Bausch + Lomb Form 8-K; Fierce Pharma report",
      "as_of": "2026-10-12"
    },
    {
      "claim": "Bausch Health holds about 87% of Bausch + Lomb. Any separation through a sale, a distribution or both depends on reaching target debt ratios and obtaining approvals.",
      "source": "Bausch Health Form 10-Q for the quarter ended 2026-09-30",
      "as_of": "2026-09-30"
    },
    {
      "claim": "Chief accounting officer Frederick Munsch exercised options on 112,015 shares and sold 112,015 shares on the open market at $20.48.",
      "source": "SEC Form 4 filed 2026-11-02",
      "as_of": "2026-10-29"
    },
    {
      "claim": "HC Wainwright cut its rating to Neutral from Buy and raised its target to $22 from $21.",
      "source": "HC Wainwright note reported by Benzinga, 2026-11-02",
      "as_of": "2026-11-02"
    },
    {
      "claim": "Carl Icahn cut his Bausch + Lomb stake by 32%, to 2,378,100 shares.",
      "source": "Benzinga report, 2026-11-13",
      "as_of": "2026-11-13"
    }
  ],
  "view_changes": [],
  "frame": {
    "as_of": "2026-11-16",
    "business": "Bausch + Lomb sells contact lenses, lens-care products, eye vitamins and eye drops (Vision Care), cataract and refractive-surgery equipment and implants (Surgical), and prescription eye drugs (Pharmaceuticals) to consumers, eye doctors, hospitals and pharmacies worldwide. Revenue was $1,375 million in the quarter to 2026-09-30.",
    "change": {
      "now": "On 2026-10-28 the company raised its 2026 adjusted EBITDA outlook to $1,090–1,140 million from $1,025–1,075 million, its third raise of the year. Two weeks earlier, on 2026-10-12, CEO Brent Saunders left.",
      "next": "Third-quarter adjusted EBITDA rose to $325 million from $243 million, and the operating margin widened to 11.3% from 7.4%. Long-term debt of $5,017 million still cost $95 million in interest that quarter.",
      "linked": "Bausch Health (BHC), owner of about 87%, now holds a more valuable stake to sell or distribute as it cuts debt. Alcon (ALC), Cooper Companies (COO) and Johnson & Johnson (JNJ) face a rival whose Surgical sales grew 9% and Pharmaceuticals 11%."
    },
    "priced_in": "At the 2026-11-13 close (filed inputs to 2026-10-28), the shares trade at 2.2 times sales (EV/sales) and 31.4 times operating profit (EV/EBIT), with a 3.3% free-cash-flow yield. The P/E is not meaningful after a $111 million four-quarter net loss. Those multiples hold only if revenue keeps growing near the 7.3% of the latest quarter while the operating margin widens well beyond its 11.3%.",
    "links": {
      "customers": [],
      "suppliers": [],
      "competitors": [
        {
          "ticker": "ALC",
          "url": null
        },
        {
          "ticker": "COO",
          "url": null
        },
        {
          "ticker": "JNJ",
          "url": "https://frontierpicks.com/dossiers/JNJ/"
        }
      ]
    }
  },
  "filed_numbers": {
    "as_of": "2026-11-17",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-17",
      "latest_quarter": "2026-09-30",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-10-28",
              "restated": null,
              "value_musd": 1375,
              "yoy_pct": 7.3
            },
            {
              "end": "2026-06-30",
              "filed": "2026-07-29",
              "restated": null,
              "value_musd": 1394,
              "yoy_pct": 9.1
            },
            {
              "end": "2026-03-31",
              "filed": "2026-04-29",
              "restated": null,
              "value_musd": 1244,
              "yoy_pct": 9.4
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-18",
              "restated": null,
              "value_musd": 1405,
              "yoy_pct": 9.8
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-29",
              "restated": null,
              "value_musd": 1281,
              "yoy_pct": 7.1
            },
            {
              "end": "2025-06-30",
              "filed": "2025-07-30",
              "restated": null,
              "value_musd": 1278,
              "yoy_pct": 5.1
            }
          ]
        },
        "gross_margin": {
          "status": "not reported"
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-10-28",
              "restated": null,
              "pct": 11.3
            },
            {
              "end": "2026-06-30",
              "filed": "2026-07-29",
              "restated": null,
              "pct": 6
            },
            {
              "end": "2026-03-31",
              "filed": "2026-04-29",
              "restated": null,
              "pct": 2.7
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-18",
              "restated": null,
              "pct": 8
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-29",
              "restated": null,
              "pct": 7.4
            },
            {
              "end": "2025-06-30",
              "filed": "2025-07-30",
              "restated": null,
              "pct": -0.9
            }
          ]
        },
        "pretax_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-28",
          "value_musd": 58
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-28",
          "four_quarters_end": "2026-09-30",
          "value_musd": 32,
          "four_quarters_musd": -111
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-28",
          "first_end": "2025-12-31",
          "value_musd": 554
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-28",
          "first_end": "2025-12-31",
          "value_musd": 302
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-28",
          "first_end": "2025-12-31",
          "value_musd": 252
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-28",
          "base_end": "2025-09-30",
          "pct": 2.1
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-28",
          "value_musd": 513
        },
        "debt": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-28",
          "value_musd": 5017,
          "composition": "long-term debt"
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-28",
          "value_musd": -4504
        },
        "deferred_revenue": {
          "status": "not reported"
        },
        "backlog": {
          "status": "not reported"
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-28",
          "value_musd": 1147
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-28",
          "value_musd": 1007
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-28",
          "value_musd": 6439
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-10-21",
          "basis_filed": "2026-10-28",
          "value_musd": 7446.7
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-10-21",
          "basis_filed": "2026-10-28",
          "value_musd": 11950.7
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-10-21",
          "basis_filed": "2026-10-28",
          "multiple": 2.2
        },
        "ev_ebit": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-10-21",
          "basis_filed": "2026-10-28",
          "multiple": 31.2
        },
        "pe": {
          "status": "not meaningful"
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-10-21",
          "basis_filed": "2026-10-28",
          "multiple": 1.2
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-10-21",
          "basis_filed": "2026-10-28",
          "pct": 3.4
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-30",
      "published": "2026-11-10",
      "short_pct_of_outstanding": 0.72,
      "days_to_cover": 2.3,
      "change_pct": 1.9
    },
    "insiders": {
      "status": "not available yet",
      "as_of": null,
      "windows": []
    }
  },
  "body_markdown": "## Current Thesis\n\nBausch + Lomb's profit recovery is real. Still, the shares are more likely to lag the S&P 500 over the next three months. They rose 24.1% in three months to $21.09 on 2026-11-13, which puts them at or above most analysts' post-results targets. The company also has an interim chief executive, and its parent controls when and how the stake is separated. The fourth-quarter report and the first 2027 outlook, due early in 2027, are the next scheduled test.\n\nThe rating is Low because the main improvement is already in the price, and the remaining upside depends on an event with no date. The company's 2026-10-28 results showed adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, excluding acquired research) of $325 million, up from $243 million a year earlier. It also raised its full-year outlook for the third time in 2026. Since then, analysts have raised their targets only to $19–23. One firm downgraded the shares, and the chief accounting officer sold shares on the open market.\n\n## Bull Case\n\n- **Margins are widening quarter after quarter.** The operating margin was 11.3% in the quarter to 2026-09-30, against 7.4% a year earlier and 2.7% in the quarter to 2026-03-31, according to the company's 10-Q filings.\n- **Third guidance raise of 2026.** On 2026-10-28 the company lifted its 2026 adjusted EBITDA outlook to $1,090–1,140 million from $1,025–1,075 million. It also lifted its revenue outlook to $5,450–5,550 million from $5,440–5,540 million (third-quarter results release).\n- **All three segments grew.** Third-quarter revenue was $1,375 million, up 7% as reported and 8% in constant currency. Vision Care grew 5%, Surgical 9% and Pharmaceuticals 11% (third-quarter results release, 2026-10-28).\n- **The parent still intends to separate.** Bausch Health's 10-Q for the quarter to 2026-09-30 says it holds about 87% of Bausch + Lomb. It lists a sale of some or all of that stake, a distribution of shares to its own holders, or a mix of the two as possible routes. A whole-company sale at a premium is the main way the shares could beat the index.\n\n## Bear Case\n\n- **Price has caught up with targets.** After the results, Wells Fargo set a $19 target and JPMorgan $22 on 2026-10-29, and RBC Capital $23 the same day. HC Wainwright cut its rating to Neutral on 2026-11-02 while raising its target to $22 from $21.\n- **Leadership gap at the top.** CEO Brent Saunders left on 2026-10-12 by mutual agreement with the board, and no reason was given. Chairman Thomas Appio became interim CEO while remaining CEO of Bausch Health. No timeline for a permanent appointment has been announced.\n- **Separation depends on the parent's debt.** Bausch Health's third-quarter 10-Q ties any separation to reaching target debt ratios and obtaining approvals. Bausch Health also weighs its Xifaxan generic-drug litigation in deciding what to do with the stake. On Bausch Health's 2026-10-28 call, Appio said \"nothing has changed\" in what it had communicated before.\n- **Insiders and a known investor sold.** SEC Form 4 filings show the chief accounting officer exercised options on 112,015 shares and sold all 112,015 at $20.48 on 2026-10-29. Benzinga reported on 2026-11-13 that Carl Icahn cut his stake by 32% to 2,378,100 shares.\n- **Heavy debt and thin earnings.** On 2026-09-30 the company had $5,017 million of long-term debt and $513 million of cash. Third-quarter interest expense was $95 million. Net income over the four quarters to 2026-09-30 was a loss of $111 million.\n\n## Setup & Price Structure\n\nThe shares closed at $21.09 on 2026-11-13. That is 1.4% below the 52-week intraday high of $21.40, set on 2026-11-10, when the stock closed at $21.37. The close compares with $17.00 on 2026-08-17 and a 52-week closing low of $14.56 on 2025-11-20. On adjusted daily closes, the price sits above the 50-day moving average of $17.98 and the 200-day moving average of $16.85, both as of 2026-11-13.\n\nThe latest gains came in two sessions. The stock closed at $19.99 on 2026-11-06 and $20.96 on 2026-11-09, with no company news dated to those sessions. The close is now inside the $19–23 range of post-results analyst targets, near its top. A common market view is that shares at a 52-week high keep leading. The rating does not rest on that view, and no reliable effect has been found so far for strong stocks after large moves.\n\n## Catalyst Calendar\n\n- **~2027-02-25 (est.):** Fourth-quarter 2026 results and first 2027 outlook. This report shows whether the margin gains continue into 2027. An outlook that lifts adjusted EBITDA growth above the 2026 pace would undercut the lag call.\n\n## What Would Change Our Mind\n\nA daily close above $23.00, above RBC Capital's $23 target of 2026-10-29 (the highest of the post-results targets cited here), which would show the shares leading; or a signed agreement by Bausch Health to sell Bausch + Lomb outright.\n\n## Correlation Notes\n\nThe shares trade mainly on news from Bausch Health (BHC), which owns about 87% of them. That makes this an event-driven stock: Bausch Health's debt reduction, its Xifaxan litigation and any word on a sale or distribution move it more than sector news does. Day to day, the business competes in contact lenses and eye surgery with Alcon (ALC), Cooper Companies (COO) and Johnson & Johnson (JNJ). Currency matters: the 2026 outlook assumes a $40 million revenue boost from foreign exchange. The company says its guidance assumes it can offset 2026 tariff costs under current policy. With $5,017 million of long-term debt, borrowing costs feed directly into earnings.",
  "first_seen": "2026-11-13",
  "last_analyzed": "2026-11-16T03:33:29+00:00",
  "last_synthesized": "2026-11-16",
  "date_modified": "2026-11-16",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}